AU2013209610B2 - Methods and formulations for treating sialic acid deficiencies - Google Patents

Methods and formulations for treating sialic acid deficiencies Download PDF

Info

Publication number
AU2013209610B2
AU2013209610B2 AU2013209610A AU2013209610A AU2013209610B2 AU 2013209610 B2 AU2013209610 B2 AU 2013209610B2 AU 2013209610 A AU2013209610 A AU 2013209610A AU 2013209610 A AU2013209610 A AU 2013209610A AU 2013209610 B2 AU2013209610 B2 AU 2013209610B2
Authority
AU
Australia
Prior art keywords
sialic acid
extended release
release formulation
neuac
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2013209610A
Other languages
English (en)
Other versions
AU2013209610A1 (en
Inventor
Emil D. Kakkis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ultragenyx Pharmaceutical Inc
Original Assignee
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultragenyx Pharmaceutical Inc filed Critical Ultragenyx Pharmaceutical Inc
Publication of AU2013209610A1 publication Critical patent/AU2013209610A1/en
Application granted granted Critical
Publication of AU2013209610B2 publication Critical patent/AU2013209610B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2013209610A 2012-01-18 2013-01-18 Methods and formulations for treating sialic acid deficiencies Expired - Fee Related AU2013209610B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261588069P 2012-01-18 2012-01-18
US61/588,069 2012-01-18
US201261709549P 2012-10-04 2012-10-04
US61/709,549 2012-10-04
PCT/US2013/022167 WO2013109906A2 (en) 2012-01-18 2013-01-18 Methods and formulations for treating sialic acid deficiencies

Publications (2)

Publication Number Publication Date
AU2013209610A1 AU2013209610A1 (en) 2014-07-10
AU2013209610B2 true AU2013209610B2 (en) 2017-11-30

Family

ID=48799814

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013209610A Expired - Fee Related AU2013209610B2 (en) 2012-01-18 2013-01-18 Methods and formulations for treating sialic acid deficiencies

Country Status (9)

Country Link
EP (1) EP2804600A4 (OSRAM)
JP (2) JP2015504094A (OSRAM)
KR (1) KR20150000872A (OSRAM)
CN (1) CN104271125A (OSRAM)
AU (1) AU2013209610B2 (OSRAM)
BR (1) BR112014017587A8 (OSRAM)
CA (1) CA2862836A1 (OSRAM)
IL (1) IL233225A0 (OSRAM)
WO (1) WO2013109906A2 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9241896B2 (en) 2008-12-19 2016-01-26 Ultragenyx Pharmaceutical Inc. Methods and formulations for treating sialic acid deficiencies
BR112013000776A2 (pt) 2010-07-13 2016-05-24 Ultragenyx Pharmaceutical Inc método e formulação para tratamento de deficiência de ácido siálico
WO2013063149A1 (en) 2011-10-24 2013-05-02 Ultragenyx Pharmaceutical, Inc. Sialic acid analogs
WO2017048817A1 (en) 2015-09-14 2017-03-23 Ultragenyx Pharmaceutical Inc. Crystal forms of sialic acid or salt or solvate thereof
EP3486326A1 (en) 2017-11-21 2019-05-22 Jennewein Biotechnologie GmbH Method for the purification of n-acetylneuraminic acid from a fermentation broth
CN117969774B (zh) * 2024-04-02 2024-06-11 小仙炖霸州食品有限公司 一种自动化燕窝检测与分级系统

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008150477A2 (en) * 2007-05-31 2008-12-11 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health N-acetyl mannosamine as a therapeutic agent
WO2010131712A1 (ja) * 2009-05-15 2010-11-18 財団法人ヒューマンサイエンス振興財団 Ｇｎｅタンパク質の機能低下に起因する疾患の治療用医薬剤、食品組成物、食品添加物
WO2012009474A1 (en) * 2010-07-13 2012-01-19 Ultragenyx Pharmaceutical Inc. Method and formulations for treating sialic acid deficiencies
WO2013063149A1 (en) * 2011-10-24 2013-05-02 Ultragenyx Pharmaceutical, Inc. Sialic acid analogs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008150477A2 (en) * 2007-05-31 2008-12-11 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health N-acetyl mannosamine as a therapeutic agent
WO2010131712A1 (ja) * 2009-05-15 2010-11-18 財団法人ヒューマンサイエンス振興財団 Ｇｎｅタンパク質の機能低下に起因する疾患の治療用医薬剤、食品組成物、食品添加物
WO2012009474A1 (en) * 2010-07-13 2012-01-19 Ultragenyx Pharmaceutical Inc. Method and formulations for treating sialic acid deficiencies
WO2013063149A1 (en) * 2011-10-24 2013-05-02 Ultragenyx Pharmaceutical, Inc. Sialic acid analogs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
May Christine V Malicdan¿, "Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model", Nature Medicine, (20090517), vol. 15, no. 6 *
NCT01236898, ClinicalTrials.gov, Available from the Internet, <URL: https://clinicaltrials.gov/ct2/show/NCT01236898>, Published 7 September 2011 according to ClinicalTrials.gov, Last Retrieved 21 June 2017 *
NCT01359319, ClinicalTrials.gov Archive, Available from the Internet, <URL: https://clinicaltrials.gov/archive/NCT01359319/2012_01_17>, Published 17 January 2012 according to ClinicalTrials.gov Archive, Last Retrieved 21 June 2017 *

Also Published As

Publication number Publication date
WO2013109906A2 (en) 2013-07-25
CA2862836A1 (en) 2013-07-25
IL233225A0 (en) 2014-08-31
EP2804600A4 (en) 2015-09-02
AU2013209610A1 (en) 2014-07-10
BR112014017587A8 (pt) 2017-07-04
JP2017186381A (ja) 2017-10-12
CN104271125A (zh) 2015-01-07
KR20150000872A (ko) 2015-01-05
JP2015504094A (ja) 2015-02-05
EP2804600A2 (en) 2014-11-26
BR112014017587A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
US9554987B2 (en) Methods and formulations for treating sialic acid deficiencies
US8916195B2 (en) Sustained release formulation of naltrexone
JP2017186381A (ja) シアル酸欠乏を処置するための方法および製剤
KR20110133602A (ko) 옥시코돈 및 날록손을 포함하는 즉시 방출 제약 조성물
EP4523745A2 (en) Bis-choline tetrathiomolybdate for treating wilson disease
US20230293495A1 (en) Pharmaceutical formulations for treating diseases mediated by kdm1a
US9241896B2 (en) Methods and formulations for treating sialic acid deficiencies
US20150030676A1 (en) Stablized modified release folic acid derivative composition, its therapeutic use and methods of manufacture
EP2061448B1 (en) Sustained release formulation of naltrexone
US9572806B2 (en) Elution-stabilized preparation
KR101869127B1 (ko) 테가푸르, 기메라실 및 오테라실칼륨 함유 구강내 붕괴정
KR102545274B1 (ko) 사쿠비트릴 및 발사르탄을 포함하는 심부전 치료용 서방성 제제, 및 이를 포함하는 다중방출 복합제제와 이의 제조방법
US20240100011A1 (en) Pediatric formulations of ferric citrate
US20240100088A1 (en) Novel formulation for treating copper metabolism-associated diseases or disorders
KR100709531B1 (ko) 당뇨병성 합병증의 예방 또는 진전저지용 의약조성물
RU2773029C2 (ru) Галеновые композиции органических соединений
EA051661B1 (ru) Фармацевтическая композиция для лечения заболеваний, опосредованных kdm1a
JP2022536955A (ja) ジクロフェナミド組成物及び使用方法

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee